Since the March 15 announcement, Valeant stock has dropped from $69.04 a share to $28.98.
Moving forward, Valeant has adjusted estimates for 2016. The company predicts total revenue for the first quarter will be lower than previous projections, but the drop in revenue is expected to level off by the fourth quarter.
Valeant leadership has undergone several changes since the beginning of 2016.
In addition to Pearson’s exit, Dr. Anders Lonner stepped down from his board position March 8, citing other commitments and personal priorities.
But, despite challenges, Ross is optimistic.
“I look forward to working with the board and management, addressing open issues and restoring investor and public confidence in Valeant,” Ross said.
Ross’ fellow board member, Eshelman, also shares ties to UNC.
Eshelman — who has donated approximately $33 million since graduating from UNC in 1972 — is the namesake of the UNC Eshelman School of Pharmacy, renamed in 2008.
Valeant is hopeful Eshelman’s extensive experience in the pharmaceutical industry will strengthen its corporate practices.
Nerkar said appointing board members is complicated.
“We do have a world where boards, while they are officially elected by the shareholders, all shareholders are not equal,” he said.
For most companies, hedge funds and institutions own shares and can influence the selection of the board or opt for members of the organization to serve directly on the board.
To get the day's news and headlines in your inbox each morning, sign up for our email newsletters.
Valeant’s Nominating and Corporate Governance Committee uses a selection criteria approved by the board and considers knowledge, experience, skills, expertise and diversity.
With the appointment of Ross, Fraidin and Eshelman, the Valeant Board of Directors expands from 12 seats to 14.